用II类主要组织相容性复合体（MHC）肽进行疫苗接种可减弱针对乙酰胆碱受体（tAChR）的细胞和体液免疫反应，并抑制实验性自身免疫性重症肌无力（EAMG）的临床症状。
Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG.
作者信息
Oshima Minako, Deitiker Philip, Ashizawa Tetsuo, Atassi M Zouhair
机构信息
Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
出版信息
Autoimmunity. 2002 May;35(3):183-90. doi: 10.1080/08916930290022270.
An animal model of myasthenia gravis (MG), termed experimental autoimmune MG (EAMG), can be induced in C57BL/6 (B6, H-2b) mice by immunization with Torpedo californica acetylcholine receptor (tAChR). We have investigated the effect of vaccination with MHC class II peptide I-A beta(b)62-76 on clinical EAMG and on T cell and antibody (Ab) responses against tAChR. B6 mice were vaccinated with the peptide (25 microg/mouse) four times prior to two injections with tAChR. The incidence of clinical EAMG in vaccinated mice was 14% (3 out of 22 mice) compared to 48% (17 out of 35 mice) in control non-vaccinated or PBS-immunized mice. The T cells of the vaccinated group showed lower proliferative responses to tAChR and to T-cell epitope-containing tAChR alpha-chain peptides than the T cells of controls. In addition, the Ab responses in the vaccinated group was also lower against tAChR and some of the B-cell epitope-containing tAChR alpha-chain peptides.
一种重症肌无力（MG）动物模型，称为实验性自身免疫性MG（EAMG），可通过用加州电鳐乙酰胆碱受体（tAChR）免疫C57BL/6（B6，H-2b）小鼠诱导产生。我们研究了用MHC II类肽I-Aβ(b)62-76进行疫苗接种对临床EAMG以及针对tAChR的T细胞和抗体（Ab）反应的影响。在两次注射tAChR之前，给B6小鼠四次接种该肽（25微克/小鼠）。接种疫苗的小鼠中临床EAMG的发生率为14%（22只小鼠中有3只），而对照未接种疫苗或用PBS免疫的小鼠中为48%（35只小鼠中有17只）。接种疫苗组的T细胞对tAChR和含T细胞表位的tAChRα链肽的增殖反应低于对照组的T细胞。此外，接种疫苗组对tAChR和一些含B细胞表位的tAChRα链肽的Ab反应也较低。
Zotero 插件